Insider buying last 90 days
No open-market insider purchases were filed for MLTX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every MLTX insider filing, plotted on the chart in Gekko.Open MLTX in Gekko
NASDAQ: MLTX
MoonLake Immunotherapeutics (MLTX) Stock Analysis & Forecast
Oct 12 close
$10.68−0.14 (−1.3%)
Gekko Brief
AI summaryOct 12 closeMLTX trades at $10.68, down 1.3% on the day and below both its 50-day average of $14.18 and 200-day average of $16.68, with the 50-day sitting under the 200-day. Shares have fallen 14.6% over the past month and 45.3% over three months, though they remain up 13.9% over the past year. The 52-week range spans $8.80 to $23.29, and typical daily moves run around 5.9%.
The GekkoIndex reads 71.9, placing MLTX in the Buying zone. Gekko Fair Value stands at $15.78, putting the current price 32.3% below that mark. Analyst consensus among 9 firms shows 8 buy ratings and 1 hold, with a consensus target of $28.54, representing 167.2% upside from current levels.
Earnings are scheduled for 4 November 2026, 23 days away, falling inside a typical 20-trading-day holding window. The prior report on 10 August showed a loss of $0.84 per share against a $0.91 estimate, with shares reacting -9.1% afterward; MLTX has beaten estimates in 3 of the last 8 quarters, averaging a 3.1% absolute reaction. Seasonality over the next 20 trading days has averaged -5.1% across 5 years, positive in 2 of them. No insider, Congress, or unusual options activity appears in the recent windows.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
MoonLake Immunotherapeutics price vs fair value
Close $10.68200-day averageGekko Fair Value $15.78
MoonLake Immunotherapeutics quick facts
- Market cap
- $898.4M
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$3.83
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.08
- Volume
- 1.21M avg 1.94M
- 1-year return
- +13.9%
- Typical daily move
- ±5.9%
- Typical 20-day move
- ±9.6%
- 50-day average
- $14.18
- 200-day average
- $16.68
- Next earnings
- Nov 4
- Shares outstanding
- 85.11M
MoonLake Immunotherapeutics swing-trade checklist
MoonLake Immunotherapeutics scores 2 supportive, 0 mixed and 3 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive0 mixed3 headwinds
- Trendheadwind
Below 50 and 200-day
Close $10.68 is below the 50-day ($14.18) and 200-day ($16.68) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
71.9, Buying
Reading 71.9 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
32.3% below
Price is 32.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−5.1% on average
From this point in the calendar, the next 20 trading days averaged −5.1% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
MoonLake Immunotherapeutics stock chart and price history
MoonLake Immunotherapeutics closed at $10.68 on Oct 12, 2026, +13.9% over the past year, inside a 52-week range of $8.80 to $23.29.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −14.6%
- 3 months
- −45.3%
- 6 months
- −42.1%
- 1 year
- +13.9%
The full MLTX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MLTX in Gekko
Follow MoonLake Immunotherapeutics through every session
Put MLTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track MLTX in GekkoFree for 7 days. No credit card required.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company dedicated to researching and advancing new treatments for inflammatory disease. Its work centers on Sonelokimab, an experimental Nanobody-based compound designed to address inflammatory conditions. This candidate is being tested in Phase II trials across several indications, including hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and radiographic axial spondyloarthritis.
As a clinical-stage firm, MoonLake does not yet sell approved products; its activity is built around the clinical development of Sonelokimab, with progress measured through the ongoing mid-stage trials testing it against multiple inflammatory conditions.
MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland. Its shares are listed on the NASDAQ under the ticker MLTX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- moonlaketx.com
MoonLake Immunotherapeutics GekkoIndex: the smart money zone
MoonLake Immunotherapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 71.9, in the Buying zone, up 1.6 points over five sessions.
71.9Buying
Up 1.6 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 43 | +5.2% | +7.4% | ||
| Accumulation | 242 | +1.3% | +0.4% | ||
| Neutral | 372 | −0.9% | −0.9% | ||
| Distribution | 24 | −8.4% | −23.5% | ||
| Selling | 1 | Too few readings yet | |||
Average MLTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the MLTX price, zone by zone.Track MLTX in Gekko
Is MoonLake Immunotherapeutics stock overvalued? Gekko Fair Value
MoonLake Immunotherapeutics trades 32.3% below Gekko Fair Value of $15.78, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what MoonLake Immunotherapeutics shares are worth, recalculated every trading day.
$15.78
Gekko Fair Value, Oct 10, 2026
32.3% Undervalued
At the end of Aug 2026 the price was 9.9% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open MLTX in Gekko
MoonLake Immunotherapeutics insider and Congress trading
No open-market insider purchases were filed for MoonLake Immunotherapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in MLTX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for MLTX, plotted on the chart in Gekko.Open MLTX in Gekko
Buybacks
MoonLake Immunotherapeutics has been buying back its own shares.
- Bought back, quarter ended Dec 31, 2021
- $6K
- As a share of market cap
- 0.00%
From company filings.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold MLTX.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
MoonLake Immunotherapeutics earnings: next date and track record
MoonLake Immunotherapeutics reports on Nov 4, 2026 (23 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 4, 2026
23 days away
- EPS estimate
- −$0.77
3 of 8reports beat the EPS estimate
±3.1%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 10, 2026 | −$0.84 est −$0.91 | — | −9.1% |
| May 11, 2026 | −$0.98 est −$0.92 | — | +6.6% |
| Feb 25, 2026 | −$0.92 est −$0.98 | — | −2.9% |
| Nov 5, 2025 | −$1.10 est −$0.89 | — | +1.6% |
| Aug 5, 2025 | −$0.87 est −$0.73 | — | −1.1% |
| May 12, 2025 | −$0.63 est −$0.74 | — | +0.2% |
| Feb 26, 2025 | −$0.72 est −$0.59 | $102K | +2.6% |
| Nov 7, 2024 | −$0.56 est −$0.45 | — | +0.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
MoonLake Immunotherapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for MoonLake Immunotherapeutics is $28.54, +167.2% from the last close, from 9 firms rating the stock in the last 90 days.
$28.54consensus 12-month target, +167.2% from the last close
Now $10.68Avg $28.54
Low $17High $50
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 5 | H.C. Wainwright | $50 | +368.2% |
| Oct 5 | Wedbush | $34 | +218.4% |
| Oct 1 | TD Cowen | — | — |
| Oct 1 | Leerink Partners | $30 | +180.9% |
| Sep 30 | LifeSci Capital | $33 | +209.0% |
+7.4%average 20-day move after past Buying readings
−5.1%average move over the next 20 trading days in the last 5 years
±5.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
MoonLake Immunotherapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, MoonLake Immunotherapeutics averaged −5.1% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | 0.0% | 2 of 5 |
| Next 10 trading days | −5.2% | 0 of 5 |
| Next 15 trading days | −3.4% | 1 of 5 |
| Next 20 trading days | −5.1% | 2 of 5 |
| Next 30 trading days | −0.4% | 2 of 5 |
For scale, MLTX’s typical 20-trading-day move in either direction is about 9.6%.
MoonLake Immunotherapeutics market cap and key statistics
MoonLake Immunotherapeutics’s market cap is $898.4M and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $898.4M
- EPS, TTM
- −$3.83
- Gekko Fair Value
- $15.78
Trading
- Volume
- 1.21M
- Avg volume, 20 days
- 1.94M
- 52-week high
- $23.29
- 52-week low
- $8.80
- Shares outstanding
- 85.11M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -67.5%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.08
- Typical daily move
- ±5.9%
- Typical 20-day move
- ±9.6%
MoonLake Immunotherapeutics peers
MoonLake Immunotherapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
MoonLake Immunotherapeutics stock FAQ
What is MoonLake Immunotherapeutics’s market cap?
MoonLake Immunotherapeutics’s market cap is $898.4M at the Oct 12, 2026 close of $10.68, with 85.11M shares outstanding.
What is the MoonLake Immunotherapeutics stock forecast?
The consensus analyst 12-month price target for MoonLake Immunotherapeutics is $28.54, +167.2% from the last close. Of the 9 firms that rated the stock in the last 90 days, 8 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is MoonLake Immunotherapeutics stock overvalued or undervalued?
On Gekko’s estimate MoonLake Immunotherapeutics is undervalued: the Oct 12, 2026 close of $10.68 is 32.3% below Gekko Fair Value of $15.78. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does MoonLake Immunotherapeutics report earnings next?
MoonLake Immunotherapeutics is expected to report on Nov 4, 2026 (23 days away). Analysts expect earnings of −$0.77 per share. MoonLake Immunotherapeutics beat the earnings estimate in 3 of its last 8 reports, moving 3.1% on average across the report.
What is MoonLake Immunotherapeutics’s 52-week high and low?
MoonLake Immunotherapeutics’s 52-week high is $23.29 and its 52-week low is $8.80; it closed at $10.68 on Oct 12, 2026, +13.9% over the past year. Over the last five years the shares peaked at $64.98 on Feb 12, 2024.
Is MoonLake Immunotherapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value) and 3 as headwinds (trend, earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See MoonLake Immunotherapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.